News | February 06, 2008

Abiomed Third Quarter Revenues Surge 24 Percent

February 7, 2008 - Abiomed Inc. reported its third quarter fiscal 2008 revenue reached $16.0 million, up 24 percent compared to revenue of $12.9 million for the same period of fiscal 2007, marking a revenue high for Abiomed.

Total revenue for the third quarter of fiscal 2008 was, and Revenue in both the U.S. and Europe were also record highs for a quarter. Revenue for the nine months ended December 31, 2007 was $41.4 million, up 13 percent compared to revenue of $36.8 million in the first nine months of fiscal 2007.

During the third quarter of fiscal 2008 compared to the third quarter of fiscal 2007, Impella disposable revenue increased 192 percent, AB5000(R) disposable revenue increased 4 percent and BVS 5000 disposable revenue declined 3 percent. During the third quarter of fiscal 2008 compared to the third quarter of fiscal 2007, Impella console revenue increased 100 percent and AB5000 console revenue decreased 12 percent.
Abiomed today updated its full year revenue forecast for its fiscal year 2008 ending March 31, 2008, to be in the range of $58 million to $62 million based on the timing of U.S. clinical trials and global regulatory approvals of new products. This forecast would be an increase over fiscal 2007 of approximately 15 to 22 percent.

For more information: www.abiomed.com

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init